- Home
- XENE vs ZLAB Comparison
XENE vs ZLAB Comparison
Compare XENE & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XENE
- ZLAB
- Stock Information
- Founded
- XENE 1996
- ZLAB 2013
- Country
- XENE Canada
- ZLAB China
- Employees
- XENE N/A
- ZLAB N/A
- Industry
- XENE Biotechnology: Pharmaceutical Preparations
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- XENE Health Care
- ZLAB Health Care
- Exchange
- XENE Nasdaq
- ZLAB Nasdaq
- Market Cap
- XENE 3.3B
- ZLAB 3.0B
- IPO Year
- XENE 2014
- ZLAB 2017
- Fundamental
- Price
- XENE $40.68
- ZLAB $26.85
- Analyst Decision
- XENE Strong Buy
- ZLAB Strong Buy
- Analyst Count
- XENE 9
- ZLAB 4
- Target Price
- XENE $56.67
- ZLAB $52.50
- AVG Volume (30 Days)
- XENE 361.3K
- ZLAB 960.6K
- Earning Date
- XENE 11-12-2024
- ZLAB 11-12-2024
- Dividend Yield
- XENE N/A
- ZLAB N/A
- EPS Growth
- XENE N/A
- ZLAB N/A
- EPS
- XENE N/A
- ZLAB N/A
- Revenue
- XENE N/A
- ZLAB $355,748,000.00
- Revenue This Year
- XENE N/A
- ZLAB $48.50
- Revenue Next Year
- XENE $1,599.99
- ZLAB $47.37
- P/E Ratio
- XENE N/A
- ZLAB N/A
- Revenue Growth
- XENE N/A
- ZLAB 35.01
- 52 Week Low
- XENE $35.53
- ZLAB $13.48
- 52 Week High
- XENE $50.99
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- XENE 46.22
- ZLAB 45.71
- Support Level
- XENE $38.95
- ZLAB $25.85
- Resistance Level
- XENE $41.62
- ZLAB $29.87
- Average True Range (ATR)
- XENE 1.46
- ZLAB 1.05
- MACD
- XENE -0.13
- ZLAB -0.18
- Stochastic Oscillator
- XENE 38.06
- ZLAB 21.98
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.